COVID-19: Cardio-pulmonary and Vascular Manifestations

Meinrad Gawaz; Rüdiger E. Scharf

doi:10.1055/a-1370-0231

Hämostaseologie, Table of Contents

Hamostaseologie 2021; 41(05): 347-348
DOI: 10.1055/a-1370-0231

Editorial

COVID-19: Cardio-pulmonary and Vascular Manifestations

Meinrad Gawaz

¹Department of Cardiology and Angiology, Eberhard Karls University Tübingen, Tübingen, Germany

,

Rüdiger E. Scharf

²Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA

³Department of Pediatrics, Harvard Medical School, Boston, MA, USA

⁴Division of Experimental and Clinical Hemostasis, Hemotherapy, and Transfusion Medicine, and Hemophilia Comprehensive Care Center, Institute of Transplantation Diagnostics and Cell Therapy, Heinrich Heine University Medical Center, Düsseldorf, Germany

› Author Affiliations

Abstract

The COVID-19 pandemic is still threatening us, our patients, and the global health care system. Since the first outbreak at the end of 2019 in China, it became rapidly clear that a new variant of a SARS virus, SARS-CoV-2, is threatening our human society worldwide. Since then, the scientific community has accumulated an incredibly large amount of knowledge about the pathophysiology of this virus, primarily affecting the respiratory tract and, in severe cases, subsequently resulting in acute respiratory distress syndrome and multiple organ failure due to uncontrolled systemic inflammatory response syndrome.[1] [2]

Full Text

References

References
1 Guzik TJ, Mohiddin SA, Dimarco A. et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020; 116 (10) 1666-1687
2 Mueller KAL, Langnau C, Günter M. et al. Numbers and phenotype of non-classical CD14^dimCD16⁺ monocytes are predictors of adverse clinical outcome in patients with coronary artery disease and severe SARS-CoV-2 infection. Cardiovasc Res 2021; 117 (01) 224-239
3 Harrison SL, Buckley BJR, Rivera-Caravaca JM, Zhang J, Lip GYH. Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews. Eur Heart J Qual Care Clin Outcomes 2021; 7 (04) 330-339
4 Zdanyte M, Rath D.. Cardiovascular risk assessment in COVID-19. Hamostaseologie 2021; 41: 348-353
5 Mizera L, Borst O. COVID-19 and the incidence of acute myocardial injury. Hamostaseologie 2021; 41: 354-362
6 Escher R, Breakey N, Lammle B. ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients. Thrombosis research 2020; 192: 174-175
7 Escher R, Breakey N, Lammle B. Severe COVID-19 infection associated with endothelial activation. Thrombosis research 2020; 190: 62
8 Mancini I, Baronciani L, Artoni A. et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. Journal of thrombosis and haemostasis: JTH 2021; 19: 513-521
9 Ward SE, Curley GF, Lavin M. et al. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. British journal of haematology 2021; 192: 714-719
10 Greulich S, Klingel K. COVID-19 and myocarditis: findings from cardiac magnetic resonance imaging and endomyocardial biopsies. Hamostaseologie 2021; 41: 364-368
11 Duckheim M, Schreieck J.. COVID-19 and cardiac arrhythmias. Hamostaseologie 2021; 41: 369-375
12 Rohlfing A-K, Rath D, Geisler T, Gawaz M. Platelets and COVID-19. Hamostaseologie 2021; 41: 376-382
13 Gawaz A. Microvascular skin manifestations caused by COVID-19. Hamostaseologie 2021; 41: 383-392
14 Pravdic Z, Bogdanovic A, Virijevic M, Sabljic N, Pantic N, Vukovic NS. COVID-19 presented with deep vein thrombosis in a patient with paroxysmal nocturnal haemoglobinuria. Hamostaseologie 2021; 41: 394-396
15 Appenzeller FF, Schmehl J, Gawaz M, Müller II. Extensive thromboembolism in a young male with asymptomatic COVID-19 infection and heterozygous factor V Leiden mutation. Hamostaseologie 2021; 41: 398-400